Skip to Content

Implanon NXT, 68 mg, implant for subdermal use (etonogestrel) – Extension of use to allow insertion immediately postpartum and immediately postabortion

01/05/2024
Medicines for human use Product information update (PIU)

This update is to inform healthcare professionals of a recent update to the product information for Implanon NXT, 68mg implant for subdermal use (etonogestrel). This update relates to extending the use of Implanon NXT to allow insertion immediately postpartum (IPP) and immediately postabortion (IPA).

Please see the document linked below for further information.

Product information

Active substance
Etonogestrel
Authorisation holder
Organon Pharma (Ireland) Limited
Authorisation number
PA23198/017/001
Human or veterinary medicine
Human Medicine

Documents

Opens in new window Implanon NXT, 68 mg, implant for subdermal use Product Information Update 1st May 2024 PDF : 102KB | 01/11/2024